← Back to Clinical Trials
Recruiting NCT07511491

NCT07511491 Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07511491
Status Recruiting
Phase
Sponsor Tanta University
Condition Ondansetron
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2026-04-11
Primary Completion 2026-10-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
Ondansetron lozengeOndansetron intravenous

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2026-04-11 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 40 years. * American Society of Anesthesiology (ASA) physical status II. * Parturient women undergoing cesarean section under spinal anesthesia. Exclusion Criteria: * Parturient women with any contraindication or hypersensitivity to the study drugs. * Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial. * Preoperative shivering. * Preoperative fever (\>38°C). * Body mass index \> 40 kg/m2. * Medical history of alcohol or drug abuse. * Hypo- or hyperthyroidism. * Parkinson's disease or any extrapyramidal disease. * Intraoperative blood transfusion.

Contact & Investigator

Central Contact

Mohammed S Elsharkawy, MD

✉ mselsharkawy@med.tanta.edu.eg

📞 00201148207870

Frequently Asked Questions

Who can join the NCT07511491 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Ondansetron. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07511491 currently recruiting?

Yes, NCT07511491 is actively recruiting participants. Contact the research team at mselsharkawy@med.tanta.edu.eg for enrollment information.

Where is the NCT07511491 trial being conducted?

This trial is being conducted at Tanta, Egypt.

Who is sponsoring the NCT07511491 clinical trial?

NCT07511491 is sponsored by Tanta University. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology